ConductScience.org, home

Paper32695101

Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal.

Bianchi V and 2 others. Front Immunol, 2020. Cited by 39 papers, by iCite.

Cite this record

ConductScience Library. Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal. Papers, record 32695101. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32695101

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal.
PubMed
Journal
Front Immunol
PubMed
Year
2020
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
39
iCite
Relative citation ratio, by iCite
1.35
iCite
Revised in PubMed
2021-04-12
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bianchi VValentina
2Harari AAlexandre
3Coukos GGeorge

Source PubMed

Download CSV of authors

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antigens, NeoplasmMajor topic
Immunotherapy, AdoptiveMajor topic
T-Cell Antigen Receptor SpecificityMajor topic
T-LymphocytesMajor topic
Animals
Biomarkers
Cells, Cultured
Clinical Studies as Topic
Coculture Techniques
Cytokines
Epitopes, T-Lymphocyte
HLA Antigens
Humans
Lymphocyte Activation
Lymphocytes, Tumor-Infiltrating
Precision Medicine
Protein Binding
T-Lymphocyte Subsets
Treatment Outcome

Source PubMed

Download CSV of topics

References133

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130418433High-throughput determination of the antigen specificities of T cell receptors in single cells.Nat Biotechnol2018https://conductscience.org/library/papers/30418433PubMed
231831802One-step artificial antigen presenting cell-based vaccines induce potent effector CD8 T cell responses.Sci Rep2019https://conductscience.org/library/papers/31831802PubMed
328628092Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer.Nat Immunol2017https://conductscience.org/library/papers/28628092PubMed
429769722Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates.Nature2018https://conductscience.org/library/papers/29769722PubMed
515931392Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells.J Clin Invest2005https://conductscience.org/library/papers/15931392PubMed
629617662Driver Fusions and Their Implications in the Development and Treatment of Human Cancers.Cell Rep2018https://conductscience.org/library/papers/29617662PubMed
720408898MHC class II epitope predictive algorithms.Immunology2010https://conductscience.org/library/papers/20408898PubMed
826901407Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients.Nat Med2016https://conductscience.org/library/papers/26901407PubMed
925304728Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma.J Immunother2014https://conductscience.org/library/papers/25304728PubMed
1028867556Neoantigen Vaccines Pass the Immunogenicity Test.Trends Mol Med2017https://conductscience.org/library/papers/28867556PubMed
119636188Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice.Proc Natl Acad Sci U S A1998https://conductscience.org/library/papers/9636188PubMed
1224048523MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia.Sci Transl Med2013https://conductscience.org/library/papers/24048523PubMed
1319543285Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers.Nat Methods2009https://conductscience.org/library/papers/19543285PubMed
1431611695Predicting HLA class II antigen presentation through integrated deep learning.Nat Biotechnol2019https://conductscience.org/library/papers/31611695PubMed
15289475674-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer.Clin Cancer Res2017https://conductscience.org/library/papers/28947567PubMed
1625765070Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.Science2015https://conductscience.org/library/papers/25765070PubMed
1729853601T-cell Responses to TP53 "Hotspot" Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers.Clin Cancer Res2018https://conductscience.org/library/papers/29853601PubMed
1822576345Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes.J Immunother2012https://conductscience.org/library/papers/22576345PubMed
1931011208Immunogenic neoantigens derived from gene fusions stimulate T cell responses.Nat Med2019https://conductscience.org/library/papers/31011208PubMed
2030683863Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients.Nat Commun2019https://conductscience.org/library/papers/30683863PubMed

See all 133 referencesDownload CSV of references

Cited by29

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 39 citations.

PMIDTitleJournalYearIn PapersSource
42461475Nonsense-mediated mRNA decay as a gatekeeper of neoantigen expression: Bridging RNA surveillance and tumor immunotherapy.Mol Biol Rep2026https://conductscience.org/library/papers/42461475PubMed
42316257Cellular immunotherapy in melanoma: the next frontier in cancer treatment.J Exp Clin Cancer Res2026https://conductscience.org/library/papers/42316257PubMed
42099613NeoTCRseek: an integrated platform for high-sensitivity identification of neoantigen-specific TCR clonotypes to track clinical T-cell dynamics.Front Immunol2026https://conductscience.org/library/papers/42099613PubMed
42027953Molecular origin, discovery, validation and application of neoantigens.Asian J Pharm Sci2026https://conductscience.org/library/papers/42027953PubMed
41740058Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next-Generation Approaches.Adv Sci (Weinh)2026https://conductscience.org/library/papers/41740058PubMed
41669116Leveraging T cells for cancer immunotherapy.Immun Inflamm2025https://conductscience.org/library/papers/41669116PubMed
40574854Breaking down physical barriers: strategies to improve lymphocyte infiltration for effective neoantigen-based therapies.Front Immunol2025https://conductscience.org/library/papers/40574854PubMed
40517350Emerging frontiers in adoptive cell therapies: innovations, challenges, and future perspectives.Med Oncol2025https://conductscience.org/library/papers/40517350PubMed
40165973T-cell receptors identified by a personalized antigen-agnostic screening approach target shared neoantigen KRAS Q61H.Front Immunol2025https://conductscience.org/library/papers/40165973PubMed
39902862Isolation of a tumor neoantigen specific CD8+ TCR from a skin biopsy of a vaccination site.Oncoimmunology2025https://conductscience.org/library/papers/39902862PubMed
39753970Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial.Nat Med2025https://conductscience.org/library/papers/39753970PubMed
39264449Recent clinical researches and technological development in TIL therapy.Cancer Immunol Immunother2024https://conductscience.org/library/papers/39264449PubMed
37700856Individualised adjuvant immunotherapy with neoantigen-reactive T cells for gastric signet-ring cell carcinoma.Clin Transl Immunology2023https://conductscience.org/library/papers/37700856PubMed
37650579Groundwork for AI: Enforcing a benchmark for neoantigen prediction in personalized cancer immunotherapy.Soc Stud Sci2023https://conductscience.org/library/papers/37650579PubMed
37420174The use of RNA-based treatments in the field of cancer immunotherapy.Mol Cancer2023https://conductscience.org/library/papers/37420174PubMed
36569859Enhancing CAR T-cell therapies against solid tumors: Mechanisms and reversion of resistance.Front Immunol2022https://conductscience.org/library/papers/36569859PubMed
36485001Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future.Clin Cancer Res2023https://conductscience.org/library/papers/36485001PubMed
36249685Tumor-Infiltrating T Cells Can Be Expanded Successfully from Primary Uveal Melanoma after Separation from Their Tumor Environment.Ophthalmol Sci2022https://conductscience.org/library/papers/36249685PubMed
35311072Cancer Neoantigens: Challenges and Future Directions for Prediction, Prioritization, and Validation.Front Oncol2022https://conductscience.org/library/papers/35311072PubMed
34707600Rapid Identification of the Tumor-Specific Reactive TIL Repertoire via Combined Detection of CD137, TNF, and IFNγ, Following Recognition of Autologous Tumor-Antigens.Front Immunol2021https://conductscience.org/library/papers/34707600PubMed

See all 29 cited byDownload CSV of cited by

Genes19

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
BRAF673PubTator's text mininghttps://conductscience.org/library/genes/673NCBI Gene
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920NCBI Gene
CD40LG959PubTator's text mininghttps://conductscience.org/library/genes/959NCBI Gene
CD80941PubTator's text mininghttps://conductscience.org/library/genes/941NCBI Gene
CD86942PubTator's text mininghttps://conductscience.org/library/genes/942NCBI Gene
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
CTLA41493PubTator's text mininghttps://conductscience.org/library/genes/1493NCBI Gene
ENTPD1953PubTator's text mininghttps://conductscience.org/library/genes/953NCBI Gene
HLA-C3107PubTator's text mininghttps://conductscience.org/library/genes/3107NCBI Gene
IFNG3458PubTator's text mininghttps://conductscience.org/library/genes/3458NCBI Gene
IL23558PubTator's text mininghttps://conductscience.org/library/genes/3558NCBI Gene
IL2159067PubTator's text mininghttps://conductscience.org/library/genes/59067NCBI Gene
ITGAE3682PubTator's text mininghttps://conductscience.org/library/genes/3682NCBI Gene
NR1I39970PubTator's text mininghttps://conductscience.org/library/genes/9970NCBI Gene
TNFRSF1A7132PubTator's text mininghttps://conductscience.org/library/genes/7132NCBI Gene
TNFRSF47293PubTator's text mininghttps://conductscience.org/library/genes/7293NCBI Gene
TNFRSF93604PubTator's text mininghttps://conductscience.org/library/genes/3604NCBI Gene
TNFSF98744PubTator's text mininghttps://conductscience.org/library/genes/8744NCBI Gene
TRBV20OR9-26962PubTator's text mininghttps://conductscience.org/library/genes/6962NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32695101

GET https://conductscience.org/api/papers/v1/32695101/references?page=2